John Sourbeer
Stock Analyst at UBS
(0.71)
# 3,428
Out of 4,667 analysts
39
Total ratings
33.33%
Success rate
-22%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.72 | +16.28% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $131.68 | +10.12% | 3 | Nov 5, 2024 | |
| QDEL QuidelOrtho | Upgrades: Neutral | $42 → $50 | $37.48 | +33.40% | 2 | Sep 19, 2024 | |
| OMIC Singular Genomics Systems | Maintains: Neutral | $12 → $15 | $21.68 | -30.81% | 2 | Mar 20, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $15 → $17 | $6.57 | +158.75% | 4 | Mar 15, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $326.09 | +47.20% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $2.16 | +247.22% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $53.37 | +91.12% | 3 | Mar 1, 2024 | |
| WST West Pharmaceutical Services | Maintains: Neutral | $400 → $375 | $311.66 | +20.32% | 2 | Feb 16, 2024 | |
| CTLT Catalent | Downgrades: Neutral | $58 → $64 | $59.00 | +7.63% | 6 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $49 → $43 | $42.09 | +2.78% | 3 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $13.32 | +275.38% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $203.67 | +32.57% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $115.93 | +10.41% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $18.27 | +20.42% | 1 | Aug 10, 2021 |
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.72
Upside: +16.28%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $131.68
Upside: +10.12%
QuidelOrtho
Sep 19, 2024
Upgrades: Neutral
Price Target: $42 → $50
Current: $37.48
Upside: +33.40%
Singular Genomics Systems
Mar 20, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $21.68
Upside: -30.81%
Cryoport
Mar 15, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $6.57
Upside: +158.75%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $326.09
Upside: +47.20%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $2.16
Upside: +247.22%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $53.37
Upside: +91.12%
West Pharmaceutical Services
Feb 16, 2024
Maintains: Neutral
Price Target: $400 → $375
Current: $311.66
Upside: +20.32%
Catalent
Feb 6, 2024
Downgrades: Neutral
Price Target: $58 → $64
Current: $59.00
Upside: +7.63%
Nov 2, 2023
Maintains: Neutral
Price Target: $49 → $43
Current: $42.09
Upside: +2.78%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $13.32
Upside: +275.38%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $203.67
Upside: +32.57%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $115.93
Upside: +10.41%
Aug 10, 2021
Initiates: Neutral
Price Target: $22
Current: $18.27
Upside: +20.42%